Risankizumab + Placebo for Risankizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Genital Psoriasis
Conditions
Genital Psoriasis, Scalp Psoriasis
Trial Timeline
Aug 10, 2023 → Nov 28, 2025
NCT ID
NCT05969223About Risankizumab + Placebo for Risankizumab
Risankizumab + Placebo for Risankizumab is a approved stage product being developed by AbbVie for Genital Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05969223. Target conditions include Genital Psoriasis, Scalp Psoriasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05969223 | Approved | Completed |
| NCT03926169 | Phase 2 | Completed |
| NCT03398135 | Phase 3 | Active |
| NCT03000075 | Phase 2 | Completed |
| NCT02719171 | Phase 2 | Completed |
Competing Products
20 competing products in Genital Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| ASP2151 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP2151 + valacyclovir + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tildrakizumab 100 mg + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Gemcitabine + Paclitaxel + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Daratumumab | Johnson & Johnson | Phase 2 | 52 |
| Ropivacaine + Epinephrine + Decadron + Clonidine + Propofol | Merck | Phase 3 | 77 |